We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
The current CRVS market cap is 100.53M. The company's latest EPS is USD -0.5512 and P/E is -3.45.
| Quarter End | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -12.47M | -15.67M | -6.57M | -8.64M | -6.43M |
| Net Income | -14.83M | -9.82M | -7.87M | -6.5M | -6M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -48.85M | -43.99M | -43.46M | -42.57M | -28.69M |
| Net Income | -46.67M | -6M | -43.24M | -41.31M | -27.03M |
| Quarter End | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 80.35M | 68.24M | 58.2M | 58.04M | 51.94M |
| Total Liabilities | 15.67M | 12.13M | 9.33M | 8.56M | 7.65M |
| Total Equity | 64.68M | 56.12M | 48.87M | 49.48M | 44.29M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 83.65M | 85.53M | 109.46M | 68.24M | 45.55M |
| Total Liabilities | 12.54M | 13.38M | 12.29M | 12.13M | 6.87M |
| Total Equity | 71.11M | 72.15M | 97.16M | 56.12M | 38.68M |
| Quarter End | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -19.48M | -27.02M | -8.11M | -13.33M | -18.77M |
| Investing | -19.39M | -23.28M | 4.6M | 313k | 17.86M |
| Financing | N/A | N/A | 4k | 7.52M | 7.86M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -37.32M | -34.78M | -36.72M | -27.02M | -23.94M |
| Investing | 3.26M | 44.77M | 21.56M | -23.28M | 15.54M |
| Financing | 24k | 1.31M | 62.16M | N/A | 7.86M |
| Market Cap | 100.53M |
| Price to Earnings Ratio | -3.45 |
| Price to Sales Ratio | 0 |
| Price to Cash Ratio | 7.38 |
| Price to Book Ratio | 2.41 |
| Dividend Yield | - |
| Shares Outstanding | 49.04M |
| Average Volume (1 week) | 169.33k |
| Average Volume (1 Month) | 137.87k |
| 52 Week Change | 99.03% |
| 52 Week High | 4.19 |
| 52 Week Low | 1.03 |
| Spread (Intraday) | 1.13 (51.36%) |
| Company Name | Corvus Pharmaceuticals Inc |
| Address |
1209 orange street wilmington, delaware 19801 |
| Website | https://www.corvuspharma.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
